These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 19651197)

  • 1. Levodopa delivery systems for the treatment of Parkinson's disease: an overview.
    Goole J; Amighi K
    Int J Pharm; 2009 Oct; 380(1-2):1-15. PubMed ID: 19651197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levodopa delivery systems: advancements in delivery of the gold standard.
    Ngwuluka N; Pillay V; Du Toit LC; Ndesendo V; Choonara Y; Modi G; Naidoo D
    Expert Opin Drug Deliv; 2010 Feb; 7(2):203-24. PubMed ID: 20095943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential nondopaminergic drugs for Parkinson's disease.
    Silverdale MA; Fox SH; Crossman AR; Brotchie JM
    Adv Neurol; 2003; 91():273-91. PubMed ID: 12442686
    [No Abstract]   [Full Text] [Related]  

  • 4. Levodopa therapeutics for Parkinson's disease: new developments.
    LeWitt PA
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S31-4. PubMed ID: 19131040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.
    Fox SH; Chuang R; Brotchie JM
    Prog Brain Res; 2008; 172():479-94. PubMed ID: 18772047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mapping neuronal activity of the basal ganglia in experimental models of Parkinson's disease: contributions of the [14C]2-deoxyglucose method.
    Orzi F; Fornai F; Blandini F
    Funct Neurol; 2000; 15(4):269-76. PubMed ID: 11213530
    [No Abstract]   [Full Text] [Related]  

  • 7. [Parkinson's disease: neuro-anatomical, biochemical and pharmicotherapeutic aspects].
    Korf J; van Praagen HM; Lakke JP
    Ned Tijdschr Geneeskd; 1975 Sep; 119(36):1373-8. PubMed ID: 241026
    [No Abstract]   [Full Text] [Related]  

  • 8. [Perioperative management of a patient with Parkinson's disease with intravenous infusion of levodopa].
    Mizuno J; Kato S; Watada M; Morita S
    Masui; 2009 Oct; 58(10):1286-9. PubMed ID: 19860235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synaptic plasticity, dopamine and Parkinson's disease: one step ahead.
    Calabresi P; Mercuri NB; Di Filippo M
    Brain; 2009 Feb; 132(Pt 2):285-7. PubMed ID: 19168452
    [No Abstract]   [Full Text] [Related]  

  • 10. Reevaluation of levodopa therapy for the treatment of advanced Parkinson's disease.
    Yokochi M
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S25-30. PubMed ID: 19131038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serotonin modulation of the basal ganglia circuitry: therapeutic implication for Parkinson's disease and other motor disorders.
    Di Matteo V; Pierucci M; Esposito E; Crescimanno G; Benigno A; Di Giovanni G
    Prog Brain Res; 2008; 172():423-63. PubMed ID: 18772045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding the dopaminergic deficits in Parkinson's disease: insights into disease heterogeneity.
    Lewis SJ; Barker RA
    J Clin Neurosci; 2009 May; 16(5):620-5. PubMed ID: 19285870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The hypothesis of the genesis of motor complications and continuous dopaminergic stimulation in the treatment of Parkinson's disease.
    Stocchi F
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S9-S15. PubMed ID: 19131046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New non-oral drug delivery systems for Parkinson's disease treatment.
    Md S; Haque S; Sahni JK; Baboota S; Ali J
    Expert Opin Drug Deliv; 2011 Mar; 8(3):359-74. PubMed ID: 21314492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent developments in Parkinson's disease and Huntington's chorea.
    Barbeau A
    Int J Neurol; 1976; 11(1):17-27. PubMed ID: 138661
    [No Abstract]   [Full Text] [Related]  

  • 16. Advances and challenges in the dosage form design for the treatment of Parkinson's disease.
    Wen MM
    Discov Med; 2012 Dec; 14(79):369-77. PubMed ID: 23272689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early dopamine agonist treatment in Parkinson's disease.
    Rinne UK
    Adv Neurol; 1990; 53():417-9. PubMed ID: 1978520
    [No Abstract]   [Full Text] [Related]  

  • 18. Localization and physiological roles of metabotropic glutamate receptors in the direct and indirect pathways of the basal ganglia.
    Marino MJ; Awad H; Poisik O; Wittmann M; Conn PJ
    Amino Acids; 2002; 23(1-3):185-91. PubMed ID: 12373536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Striatal and extrastriatal dopamine in the basal ganglia: an overview of its anatomical organization in normal and Parkinsonian brains.
    Smith Y; Villalba R
    Mov Disord; 2008; 23 Suppl 3():S534-47. PubMed ID: 18781680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional neuroanatomy of the basal ganglia in Parkinson's disease.
    Wichmann T; DeLong MR
    Adv Neurol; 2003; 91():9-18. PubMed ID: 12442660
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.